Jipmer enrolls first infant in NeoSep1 international clinical trial in fight against neonatal sepsis
Jipmer has become the first center in India to enroll an infant in the international NeoSep1 clinical trial. The study aims to identify effective antibiotic combinations to combat neonatal sepsis and rising antimicrobial resistance.
Why it matters
Neonatal sepsis is a leading cause of infant mortality, and this research could establish new global treatment guidelines for low and middle-income countries.
Jawaharlal Institute of Postgraduate Medical Education and Research (Jipmer) has achieved a significant milestone by becoming the first centre in India to enroll a newborn in the NeoSep1 international clinical trial, a major step in the fight against neonatal sepsis and rising antimicrobial resistance (AMR).
The article reports on a medical milestone using factual, neutral language without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in